◆英語タイトル:MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C9453
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
MEI Pharma Inc (MEIP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
MEI Pharma Inc (MEI Pharma), formerly Marshall Edwards Inc, develops drugs for the treatment of cancer. The company’s drug candidates include pracinostat, an oral histone deacetylase inhibitor, intended for the treatment of advanced hematological diseases including acute myeloid leukemia and myelodysplastic syndrome; ME-344, a mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and ME-401, an oral PI3K delta inhibitor for B-cell malignancies, refractory chronic lymphocytic leukemia and follicular lymphoma. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor through agreement with Presage. MEI Pharma is headquartered in San Diego, California, the US.
MEI Pharma Inc Key Recent Developments
Nov 01,2018: MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting
Aug 30,2018: MEI Pharma reports fiscal year 2018 results and operational highlights
Aug 29,2018: MEI Pharma To Present at Wells Fargo Securities 2018 Healthcare Conference
Jul 16,2018: MEI Pharma announces promotion of David M. Urso to chief operating officer
May 14,2018: MEI Pharma Announces $75 Million Private Placement
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
MEI Pharma Inc – Key Facts 6
MEI Pharma Inc – Key Employees 7
MEI Pharma Inc – Key Employee Biographies 8
MEI Pharma Inc – Major Products and Services 9
MEI Pharma Inc – History 10
MEI Pharma Inc – Company Statement 11
MEI Pharma Inc – Locations And Subsidiaries 12
Head Office 12
Section 2 – Company Analysis 13
Company Overview 13
MEI Pharma Inc – Business Description 14
MEI Pharma Inc – Corporate Strategy 15
MEI Pharma Inc – SWOT Analysis 16
SWOT Analysis – Overview 16
MEI Pharma Inc – Strengths 16
MEI Pharma Inc – Weaknesses 17
MEI Pharma Inc – Opportunities 18
MEI Pharma Inc – Threats 19
MEI Pharma Inc – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
MEI Pharma Inc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Nov 01, 2018: MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting 31
Aug 30, 2018: MEI Pharma reports fiscal year 2018 results and operational highlights 35
May 14, 2018: MEI Pharma Announces $75 Million Private Placement 37
May 09, 2018: MEI Pharma Reports Third Quarter Fiscal Year 2018 Results 38
Feb 08, 2018: MEI Pharma Reports Second Quarter Fiscal Year 2018 Results 40
Nov 08, 2017: MEI Pharma Reports First Quarter Fiscal Year 2018 Results 42
Sep 05, 2017: MEI Pharma Reports Fiscal Year 2017 Results 43
May 04, 2017: MEI Pharma Reports Third Quarter Fiscal Year 2017 Results 45
Apr 03, 2017: MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer 46
Feb 08, 2017: MEI Pharma Reports Second Quarter Fiscal Year 2017 Results 47
Section 6 – Appendix 49
Methodology 49
Ratio Definitions 49
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Tables
MEI Pharma Inc, Key Facts 6
MEI Pharma Inc, Key Employees 7
MEI Pharma Inc, Key Employee Biographies 8
MEI Pharma Inc, Major Products and Services 9
MEI Pharma Inc, History 10
MEI Pharma Inc, Key Competitors 20
MEI Pharma Inc, Ratios based on current share price 21
MEI Pharma Inc, Annual Ratios 22
MEI Pharma Inc, Annual Ratios (Cont...1) 23
MEI Pharma Inc, Annual Ratios (Cont...2) 24
MEI Pharma Inc, Interim Ratios 26
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
MEI Pharma Inc, Recent Deals Summary 30
Currency Codes 49
Capital Market Ratios 49
Equity Ratios 50
Profitability Ratios 50
Cost Ratios 51
Liquidity Ratios 51
Leverage Ratios 52
Efficiency Ratios 52
List of Figures
MEI Pharma Inc, Performance Chart (2014 - 2018) 25
MEI Pharma Inc, Ratio Charts 27
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
MEI Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29